BCDA - Why Is BioCardia Stock Plunging Today? | Benzinga
BioCardia Inc (NASDAQ: BCDA) shares are down after the company released interim efficacy results in the phase 3 pivotal CardiAMP cell therapy heart failure trial.
For the first tier, all-cause death, including cardiac death equivalents such as heart transplant or left ventricular assist device placement at 12 months, there were 5.6% of CardiAMP treatment patients versus 5.3% for the control group (p = 0.42).
24-month follow-up data showed a separation between groups, with 8.3% all-cause death, including cardiac death equivalents in the treatment group versus 13.2% in the control group (p = 0.94), corresponding to a 37% relative risk reduction for Tier ...